Collins’ skillful piloting helped NIH steer clear of political minefields

Julie Rovner
By Julie Rovner
Oct. 9, 2021

It’s remarkable that the reputation of the National Institutes of Health has remained mostly intact through the covid-19 pandemic, even as other federal science agencies, including the Food and Drug Administration and Centers for Disease Control and Prevention, have come under partisan fire.

NIH/Chiachi Chang
NIH Director Dr. Francis Collins gives remarks at the Washington National Cathedral's Vaccine Confidence event on March 16, 2021. After the comments concluded, 25 local religious leaders and clergy stepped forward to have their vaccines administered on camera to encourage others, when offered, to do the same.

That is in no small part due to NIH’s soft-spoken but politically astute director, Dr. Francis Collins. The motorcycle-riding, guitar-playing Collins announced Tuesday he will step down by the end of the year from his job as chief of the research agency, having served more than a dozen years under three presidents.

“No single person should serve in the position too long,” said Collins in a statement, and “it’s time to bring in a new scientist to lead the NIH into the future.” Collins, 71, said he plans to return to his lab at the National Human Genome Research Institute, which he led for 15 years, from 1993 to 2008. Under his leadership, the institute successfully mapped the human genome, and Collins helped shepherd through Congress legislation to protect the privacy of individuals’ genetic information.

The big question now is not just who will fill Collins’ big shoes at NIH, but whether the agency can maintain its status as a political favorite among members of both parties. Under Collins’ stewardship, NIH’s budget has increased by more than a third during a time of mostly flat federal health budgets, and political interference with biomedical research has been, if not nonexistent, at least mostly off the front pages. That’s in sharp contrast to the CDC, whose handling of the pandemic has drawn plenty of criticism under both Presidents Donald Trump and Joe Biden, and the FDA, which tallied its own covid missteps and remains without a nominated commissioner nearly 10 months into the new administration.

While Dr. Anthony Fauci, director of the NIH’s National Institute of Allergy and Infectious Diseases, has maintained a much higher profile than Collins and also courted controversy, most of that flak did not redound to NIH as a whole.

President Joe Biden praised Collins, calling him “one of the most important scientists of our time.” Noting Collins’ work on the human genome and his help launching the Obama administration’s work on precision medicine, the Brain Initiative and the National Cancer Moonshot effort, Biden said, “Millions of people will never know Dr. Collins saved their lives.”

Accolades for Collins flowed in from the scientific community as soon as news of his impending departure was announced. “For more than a decade Dr. Collins has provided exemplary leadership and stewardship as head of the NIH,” said the American Cancer Society Cancer Action Network.

And the praise from politicians was distinctly bipartisan. Sen. Richard Burr (R-N.C.) said in a statement that Collins “led the NIH capably and admirably, leaving it better prepared to meet the challenges of the 21st century.” House Majority Leader Steny Hoyer was no less effusive, calling Collins “one of our country’s greatest public servants, having spent his career working to improve the health of all Americans and promoting cutting-edge research that extends our understanding of the human body and how to heal it.”

It is notable that the relative lack of controversy during Collins’ tenure has been the exception, not the rule, for NIH over the past half-century. Starting in the 1970s, every biomedical advance, from in vitro fertilization to fetal tissue and stem cell research to the cloning of Dolly the sheep resulted in intense political fights and blaring headlines.

National Institutes of Health
Francis Collins speaks at a NIH campus screening of the documentary "Weight of the Nation" in 2012.

In the late 1990s, Republicans led by then-House Speaker Newt Gingrich decided to make science funding a priority and spearheaded a doubling of NIH’s budget, an effort Democrats happily joined. But after that doubling, a stagnant NIH budget caused cutbacks in university research, creating controversy of its own, which Collins had to manage.

Controversy comes with the territory. “Anytime there’s controversy in science, NIH is going to be involved,” said Mary Woolley, president and CEO of Research!America, a science funding advocacy group.

What has set Collins apart, said Woolley, is his ability to communicate to transcend that controversy, “both in ways unexpected, like singing and riding motorcycles, and more traditional ways,” like dealing with lawmakers.

Dr. Ross McKinney, chief scientific officer for the Association of American Medical Colleges, agreed. “He’s just done a dynamite job at being effective at communicating with both sides,” he said. “He’s good with scientists, he’s personally Christian and religious, so he can speak to that side, as well.”

Both Woolley and McKinney said they are confident there are plenty of good candidates to lead NIH, although neither would name any. But McKinney said he hopes the NIH doesn’t end up with a void at the top like the FDA. “I think the FDA precedent is concerning,” he said.

Still, Woolley said, Collins is leaving the NIH in good shape. “The next leader will benefit from what he has done,” she said.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Julie Rovner
Julie Rovner

Julie Rovner, who has covered health care for more than 30 years, offers insight and analysis of policies and politics in her regular HealthBent columns.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

2022 voter guide
Member News

2022 voter guide

May 23, 2022

Learn about the positions and candidates running for ASBMB Council, secretary, Publications Committee and Nominating Committee.

‘We're all a bunch of weirdos doing our stuff’

‘We're all a bunch of weirdos doing our stuff’

May 20, 2022

An interview with Charles Sanders, a research associate at XBiotech.

Meet the 2022 ASBMB Advocacy Training Program delegates

Meet the 2022 ASBMB Advocacy Training Program delegates

May 19, 2022

The fourth cohort of the ASBMB ATP will learn how to advocate for science policy this summer.

Good fellows
Editor's Note

Good fellows

May 18, 2022

“To be a fellow, a member must be generous with time and talent — not just someone whose CV includes pages of individual BMB achievements.”

ASPET announces new leadership
Member News

ASPET announces new leadership

May 16, 2022

Bumpus, Ding, Boise and Linder to assume duties this summer.

James Bryant Howard (1942 – 2022)

James Bryant Howard (1942 – 2022)

May 16, 2022

He was an ASBMB member for more than 40 years, and he served on the Journal of Biological Chemistry editorial board from 1986 to 1991.